CALLIPER study
Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients with
What was tested
Treatment tested
- Vidofludimus
Dihydroorotate dehydrogenase inhibitor
What it measured
Main measures
Annualized rate of percent brain volume change (PBVC) during MT period.
Brain volume loss
Other measures (1)
Time to 24-week confirmed disability worsening based on expanded disability status scale (EDSS) during the MT period
Disability progression
Loading reviews and guidelines…
Related trials
- CALLIPER
Phase 2 · Status unknown
No result found
- STOP-I-SEP
Phase 3 · Running, not recruiting
Still running
- TERIPET
Phase 4 · Running, not recruiting
Still running
- The effect of teriflunomide on brain microglial cell acti…
Phase 4 · Completed
History
- In scope changed from true to false
Started
Aug 2021
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error